Table 3 Combined Active and Passive Immunotherapies for Glioma Patients

Duke Univ, Durham, NC/D Mitchell

CMV-DCs ± CMV-ALT + TMZ ± Skin site preparation (unpulsed DC or tetanus toxoid)

I/II - 16

ND

IV

NCT00639639

Mitchell et al [16, 77]

Duke Univ, Durham, NC/D Mitchell

CMV-ALT ± CMV-DCs + RT + TMZ (intratumoral CMV-DC upon recurrence)

I - 12

ND

IV

NCT00693095

Mitchell et al [16, 77]

Duke Univ, Durham, NC/D Mitchell

CMV-ALT ± CMV-DC or CMV-DC ± CCR7-DC

I/II - 20

ND

IV

NCT00627224

Mitchell et al [16, 77]

St. Lukes Hosp, Kansas City, MO/M Salacz

Autologous Tumor Cells + GM-CSF → iv Activated T Cells + IL-2 (TVAX)

I/II - 10

R

III or IV

NCT01081223

Wood et al [39]